2015
DOI: 10.1016/s1470-2045(15)00121-7
|View full text |Cite
|
Sign up to set email alerts
|

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

7
286
2
11

Year Published

2016
2016
2020
2020

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 379 publications
(306 citation statements)
references
References 28 publications
7
286
2
11
Order By: Relevance
“…The data of ORR was 18% and median PFS was 4.2 months for patients with chemotherapy alone in the previous study, but the hematologic and neurologic adverse effects were much more common in chemotherapy group (22). Considering the efficacy and toxicity, afatinib could be an optional choice compared with chemotherapy alone with much (23)(24)(25). Meanwhile, for advanced EGFRpositive patients with acquired resistance, changing to other 1st generation TKIs seemed to be the inefficient treatment.…”
Section: Discussionmentioning
confidence: 86%
“…The data of ORR was 18% and median PFS was 4.2 months for patients with chemotherapy alone in the previous study, but the hematologic and neurologic adverse effects were much more common in chemotherapy group (22). Considering the efficacy and toxicity, afatinib could be an optional choice compared with chemotherapy alone with much (23)(24)(25). Meanwhile, for advanced EGFRpositive patients with acquired resistance, changing to other 1st generation TKIs seemed to be the inefficient treatment.…”
Section: Discussionmentioning
confidence: 86%
“…The IMPRESS study (phase III) conducted in this article randomized patients progressed under the gefitinib treatment into cisplatin/pemetrexed or cisplatin/pemetrexed/gefitinib. Chemotherapy combined with gefitinib did not significantly contribute to survival (PFS: 5.4 months for both arms), concluding that platinum-based combined chemotherapy was the standard approach [20].…”
Section: Combining the Egfr-tki With Other Agentsmentioning
confidence: 93%
“…For patients with active EGFR mutations, TKIs produced high response rates up to 75% and improved progression-free survival (PFS) to 9-13 months as compared with chemotherapy in randomized trials (4,(9)(10)(11). However, majority of the patients developed acquired drug resistance after initial response to TKI, and the median overall survival in those patients was estimated to 30 months.…”
Section: Historical and Current Perspectives Of Epidermal Growth Factmentioning
confidence: 99%